Kymera Therapeutics (KYMR) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Twist Bioscience (TWST) has outperformed Kymera Therapeutics (KYMR) over the past year, gaining 400.2% versus a gain of 90.4%. Over five years, KYMR leads with a +89.4% price change compared with +38.0% for TWST. Twist Bioscience is the larger company by market cap ($10.08 billion vs $8.99 billion), about 1.1 times the size.
Twist Bioscience converts more of its revenue into profit, with a net margin of -20.6% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYMR | TWST |
|---|---|---|
| Share price | $109.30 | $152.05 |
| Market cap | $8.99B | $10.08B |
| 1-day change | +0.88% | -2.31% |
| YTD return | +39.25% | +390.70% |
| 1-year return | +90.35% | +400.16% |
| 5-year return | +89.42% | +37.99% |
| EPS (TTM) | $-3.25 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $39.21M | $376.57M |
| Revenue growth (YoY) | -16.70% | +20.32% |
| Net income (latest FY) | $-311.35M | $-77.67M |
| Gross margin | 0.00% | 50.72% |
| Operating margin | -891.07% | -36.18% |
| Net margin | -794.04% | -20.63% |
| 52-week high | $130.05 | $219.71 |
| 52-week low | $55.26 | $23.30 |
| Distance from 52-week high | -15.96% | -30.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +27.47% | -12.04% |
| Average volume | 698.42K | 1.99M |
| Shares outstanding | 82.26M | 66.30M |
| Employees | 273 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed KYMR by 309.8 percentage points over the past year.
- Twist Bioscience is more profitable, keeping -20.6 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Twist Bioscience grew revenue faster in its latest fiscal year (+20.32% vs -16.70%).
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
KYMR vs TWST FAQ
Which is bigger, Kymera Therapeutics or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $10.08B compared with $8.99B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, KYMR or TWST?
TWST returned +400.16% over the past 12 months, compared with +90.35% for KYMR (price return, excluding dividends). Past performance does not predict future results.
Are Kymera Therapeutics and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.